Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Ronan J Kelly,Jaffer A Ajani,Jaroslaw Kuzdzal,Thomas Zander,Eric Van Cutsem,Guillaume Piessen,Guillermo Mendez,Josephine Feliciano,Satoru Motoyama,Astrid Lièvre,Hope Uronis,Elena Elimova,Cecile Grootscholten,Karen Geboes,Syed Nabeel Zafar,Stephanie Snow,Andrew H Ko,Kynan Feeney,Michael Schenker,Piotr Kocoń,Jenny Zhang,Lili Zhu,Ming Lei,Prianka Singh,Kaoru Kondo,James M. Cleary,Markus Moehler,CheckMate Investigators

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

2021

Abstract Background No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal...

Keywords:

Oncology
Adjuvant
Internal medicine
MEDLINE
neoadjuvant chemoradiotherapy
Gastroesophageal Junction
Medicine
Cancer
Nivolumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations